Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251810120 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Sultana Mehbuba Hossain und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Otago Medical Research Foundation, New Zealand Institute for Cancer Research Trust, New Zealand HRC programme grant.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by enhancing anti-tumour immune responses, demonstrating significant efficacy in various malignancies, including melanoma. However, over 50% of patients experience limited or no response to ICI therapy. Resistance to ICIs is influenced by a complex interplay of tumour intrinsic and extrinsic factors. This review summarizes current ICIs for melanoma and the factors involved in resistance to the treatment. We also discuss emerging evidence that the microbiota can impact ICI treatment outcomes by modulating tumour biology and anti-tumour immune function. Furthermore, microbiota profiles may offer a non-invasive method for predicting ICI response. Therefore, future research into microbiota manipulation could provide cost-effective strategies to enhance ICI efficacy and improve outcomes for melanoma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand.
ORCID-Profile: Yih Jian Sung
Förderung
- Otago Medical Research Foundation
- New Zealand Institute for Cancer Research Trust
- New Zealand HRC programme grant
- New Zealand HRC project grant
Zitieren
APA
Hossain, S. M., Ly, K., Sung, Y. J., Braithwaite, A., & Li, K. (2024). Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251810120
Vancouver
Hossain SM, Ly K, Sung YJ, Braithwaite A, Li K. Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251810120
BibTeX
@article{Hossain2024,
author = {Hossain, Sultana Mehbuba and Ly, Kevin and Sung, Yih Jian and Braithwaite, Antony and Li, Kunyu},
title = {Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251810120}
}
EUVIMED